[Pharmacological treatment of recurrent idiopathic anterior uveitis].

Jerzy Szaflik, Artur Bachta, Maciej Kulig, Mateusz Tłustochowicz, Andrzej Stankiewicz, Witold Tłustochowicz

Katedry i Kliniki Okulistyki II Wydziału Lekarskiego Warszawskiego Uniwersytetu Medycznego.

Journal Article: Klinika oczna 01/2011; 113(4-6):111-6.

Abstract

Recurrent anterior uveitis (AU) is an autoimmune disease that in 20% of patients leads to severe visual loss or blindness, thereby a severe disability and significant quality of life impairment. That is why, it is important to conduct a long term treatment after an acute phase of the disease, to keep the remission as long as possible. Up to 50% of patients with recurrent AU have no additional symptoms of systemic disease. This situation, classified as idiopathic AU (IAU), causes a lot of problems when a therapeutic strategy has to be chosen. Nevertheless, IAU is considered to be a first symptom of spondylarthropathy (SpA), even several dozen years prior to other typical manifestations of SpA. There have been published few papers concerning only small groups of patients with IAU, treated with disease modifying anti-rheumatic drugs. The authors present the recommendations for systemic treatment of IAU, based on their own clinical experience, and systematic review of the literature.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

additional symptoms
 
autoimmune disease
 
causes
 
disease modifying anti-rheumatic drugs
 
dozen years
 
first symptom
 
own clinical experience
 
patients
 
recommendations
 
Recurrent anterior uveitis
 
recurrent AU
 
severe disability
 
severe visual loss
 
small groups
 
spondylarthropathy
 
systemic disease
 
systemic treatment
 
term treatment
 
typical manifestations